阅读说明：本技术 磷脂及其衍生物在制备改善系统性红斑狼疮制品中的应用 (Application of phospholipid and derivatives thereof in preparation of products for improving systemic lupus erythematosus ) 是由 张恬恬 史豪豪 王玉明 薛长湖 姜晓明 毛相朝 薛勇 李兆杰 徐杰 王静凤 常耀 于 2021-09-10 设计创作，主要内容包括：本发明属于活性物质筛选技术领域,具体涉及一种磷脂在制备改善系统性红斑狼疮制品中的应用。包括磷脂及其糖基化衍生物,如磷脂酰胆碱、磷脂酰丝氨酸、磷脂酰乙醇胺、磷脂酰糖苷和富含DHA的磷脂。本发明通过实验研究,证实了磷脂及其衍生物在改善系统性红斑狼疮方面具有显著的改善作用,使磷脂增加了一种新用途,有产业利用价值,而且该结果可应用于在改善系统性红斑狼疮的医学临床实践,用于开发相关的药品和保健品,具有潜在的经济和社会效益。(The invention belongs to the technical field of active substance screening, and particularly relates to application of phospholipid in preparation of a product for improving systemic lupus erythematosus. Including phospholipids and their glycosylated derivatives such as phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycoside and DHA-rich phospholipids. The invention proves that the phospholipid and the derivative thereof have obvious improvement effect on the aspect of improving the systemic lupus erythematosus through experimental research, so that the phospholipid has a new application and industrial utilization value, and the result can be applied to medical clinical practice of improving the systemic lupus erythematosus and used for developing related medicines and health care products, thereby having potential economic and social benefits.)

1. Application of phospholipid and derivatives thereof in preparing products for improving systemic lupus erythematosus.

2. The use of claim 1, wherein: the phospholipids and derivatives thereof include phospholipids and glycosylated derivatives thereof.

3. Use according to claim 1 or 2, characterized in that: the phospholipid and its derivatives are one or more of phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylglucoside and DHA-rich phospholipid.

4. Use according to claim 1 or 2, characterized in that: the phospholipid and its derivatives are extracted from semen glycines or Loligo chinensis Gray ovum and separated from the semen glycines or Loligo chinensis Gray ovum.

5. The use of claim 1, wherein: the product comprises special medical food, health care products, medicines or biological agents and related products.

6. The use of claim 1, wherein: said preparation comprising a pharmacologically effective concentration of said phospholipid and derivatives thereof as defined in claim 1.

7. A process for the preparation of the phospholipids or derivatives thereof as claimed in claim 4, characterized in that it comprises the following steps: (1) freeze-drying squid eggs or soybeans, then crushing, extracting for 24 hours by using a chloroform/methanol (2: 1, V/V) mixed solution with the volume 15 times, carrying out suction filtration, and extracting for 3 times; adding sodium chloride solution, shaking, standing overnight, collecting lower chloroform layer, and concentrating under reduced pressure to obtain crude extract of squid egg or soybean lipid;

(2) separating the crude lipid extract by normal phase silica gel column chromatography, gradient eluting with chloroform and methanol (90: 10 → 60: 40 → 0: 100, V/V), collecting eluate step by step, concentrating under reduced pressure, detecting the collected components by TLC, mixing the components with the same Rf value, and concentrating under reduced pressure to dry to obtain phosphatidylcholine and phosphatidylethanolamine.

8. A process for the preparation of the phospholipids or derivatives thereof as claimed in claim 7, characterized in that: preparing a sodium acetate buffer solution with the pH value of 5.6, adding 6% of fructose and 1.5% of Lipozyme435, dissolving in a buffer solution to obtain an aqueous phase, dissolving 20% of the soybean-derived phosphatidylcholine obtained in the step (2) in methanol to obtain an organic phase, and fully mixing the aqueous phase and the organic phase, wherein the ratio of the aqueous phase to the organic phase is 1: 4; the mixture is stirred and reacted for 10 hours at 37 ℃, an organic phase layer is collected, and the organic solvent is removed to obtain the phosphatidyl glycoside.

9. A process for the preparation of the phospholipids or derivatives thereof as claimed in claim 7, characterized in that: and (3) preheating the acetic acid/sodium acetate solution buffer solution in a heat collection type constant-temperature heating magnetic stirrer, dissolving L-serine in the buffer solution, adding the phosphatidylcholine from the squid eggs in the step (2), finally adding phospholipase D, stirring at 40 ℃ for reaction for 48 hours, adding hydrochloric acid, inactivating enzyme, stopping the reaction, and extracting reaction products by using n-hexane-isopropanol to obtain soybean phosphatidylserine and DHA phosphatidylserine.

The technical field is as follows:

the invention belongs to the technical field of active substance screening, and particularly relates to application of phospholipid and derivatives thereof in preparation of products for improving systemic lupus erythematosus.

Background art:

systemic Lupus Erythematosus (SLE) is a serious chronic, recurrent diffuse connective tissue disease. SLE induces autoantigens through the interaction of various factors such as genetic, environmental, immune and hormonal factors to activate innate and adaptive immune responses of the body, induces the production of autoantibodies, and the deposition of immune complexes in tissues leads to the activation of complement and the increase of neutrophils, monocytes and autoreactive lymphocytes. SLE can cause tissue damage to various organs throughout the body, most commonly the skin and kidneys. At present, clinically therapeutic drugs for systemic lupus erythematosus mainly comprise glucocorticoids, hydroxychloroquine, cyclophosphamide and the like, and can cause toxic and side effects after long-term administration, and no drug for completely treating SLE exists clinically at present. There has been an increasing number of studies showing the importance of nutritional interventions to alleviate disease, and dietary supplementation with functional ingredients or nutritional supplements may ameliorate systemic lupus erythematosus.

Phospholipids are a class of lipids that are widely present in animal and plant tissues. Currently, the main sources of commercial phospholipids are soy and egg yolk. In addition to terrestrial organisms, phospholipids are widely found in marine animals such as fish eggs, shrimps, and shellfish and marine plants. The phospholipid of marine origin has a special structure, and the sn-2 position of the phospholipid is rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Phospholipids have important physiological effects and nutritive values, and are used in the industries of food, medicine, cosmetics, textile and the like. The phospholipid as emulsifier plays an important role in the transportation of polymer packaging films, medicaments and active substances, and has an improvement effect on liver injury, cardiovascular and cerebrovascular diseases, acute kidney injury and the like. However, no research is focused on the improvement effect of phospholipids and derivatives thereof on systemic lupus erythematosus.

The invention content is as follows:

the technical problem to be solved by the invention is that the effect of taking phospholipid and derivatives thereof on systemic lupus erythematosus is not researched clinically at present.

In order to solve the problems, the invention proves that the phospholipid and the derivative thereof have obvious improvement effect on the aspect of improving the systemic lupus erythematosus through experimental research, so that a new application of the phospholipid is added, the industrial utilization value of the phospholipid is improved, and the result can be applied to the medical clinical practice of improving the systemic lupus erythematosus and is used for developing related medicines and health care products, thereby having potential economic and social benefits.

In order to achieve the purpose, the invention is realized by the following technical scheme:

application of phospholipid and derivatives thereof in preparing products for improving systemic lupus erythematosus.

Further, the phospholipids and derivatives thereof include phospholipids and glycosylated derivatives thereof, such as phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylglycoside and DHA-rich phospholipids, where DHA can also be other marine-derived n-3 polyunsaturated fatty acids, such as EPA.

Further, the phospholipid and the derivative thereof are phospholipid extracted and separated from soybean or squid egg and the derivative thereof, and the squid egg can also be other marine foods.

The invention extracts, separates and prepares six different phospholipids from soybean and squid eggs respectively, including series I-VI, series I to III are phospholipid and phospholipid derivatives from soybean, series I is phosphatidylcholine from soybean, the sn-2 fatty acid is mainly linoleic acid, the polar head is phosphatidylcholine; the series II is soybean-derived phosphatidyl glycoside, and the polar head is phosphatidyl glycoside; line III is phosphatidylserine from soy, with the polar head being phosphatidylserine. The serial IV-VI is phospholipid derived from squid eggs, the serial IV is phosphatidylcholine rich in DHA, the sn-2 fatty acid of the serial IV-VI is mainly DHA, and the polar head is phosphatidylcholine; line V is DHA-rich phosphatidylserine, with the polar head being phosphatidylserine; series vi is a DHA-rich phosphatidylethanolamine with the polar head being phosphatidylethanolamine. All six compounds have a glycerol backbone, fatty acids and polar heads, and although they all belong to phospholipids, they differ in structure, ultimately resulting in differences in their physiological activities. First, phospholipids have different fatty acid compositions due to their different sources. The soybean phospholipid C18:2n-6 accounts for nearly 50% of fatty acid composition, and the phospholipid from sea is rich in two n-3 fatty acids of EPA and DHA. The biological activity of phospholipids is closely related to their fatty acid composition, for example, it has been found that phospholipids rich in DHA or EPA have an improved effect on metabolic syndrome and acute kidney injury over soybean phospholipids. However, the biological activity of phospholipids is sometimes not only dependent on fatty acid composition, but the polar head of phospholipids is also an important factor affecting their biological activity. The phosphatidylcholine is used as a main dietary source of the choline, and plays an important role in maintaining the functions of the liver and the kidney, lipid metabolism and transportation, cell membrane signal transmission, cell composition and repair; phosphatidylethanolamine is commonly called cephalin and has important functions of maintaining normal cell morphology, regulating cell metabolism and improving neurodegenerative diseases. Phosphatidylserine is an important component of cell membrane phospholipids and plays an important role in the repair of nerve cells and the regulation of cell metabolism. Aiming at the invention, the aim of improving the systemic lupus erythematosus is achieved by dietary intervention of phospholipid and glycosylated derivatives thereof. First, Lupus Nephritis (LN) is the most common serious complication of systemic lupus erythematosus patients, LN is also the major risk factor for death of SLE patients, and imbalance in immunoregulation is an important link in the development of LN, and irreversible renal damage caused by massive infiltration of inflammatory cells and factors in the kidney is the major cause of LN. Therefore, finding potential ways to modulate autoimmune function by inhibiting inflammatory responses is critical for the development of LN therapeutic drugs. In addition, it was shown that NF-. kappa.B activation is closely related to LN immune imbalance. NF-kB is a key inflammatory initiation factor, activation of which depends on IKK beta activity to phosphorylate IkB, and after activation, NF-kB enters into cell nucleus to promote inflammatory reaction. Therefore, the invention selectively inhibits the activity of NF-kB by interfering phospholipid and glycosylated derivatives thereof through diet, thereby achieving the purpose of improving LN-induced kidney injury. Second, studies have shown that dietary choline intake levels are thought to be inversely related to serum inflammatory factor levels, and the presence of choline in PC is one of the possible causes of the ability of yolk PC to reduce the inflammatory response. In vitro experiments indicate that two PE molecules can inhibit PAF (platelet activating factor), an inflammatory mediator involved in chronic inflammatory reactions, induced platelet aggregation. Thus, nutritional intervention with PC or PE may promote normalization of renal phospholipid composition and reduce levels of inflammation in vivo, which may also be one of the reasons why DHA-rich PC or PE is superior in efficacy to phosphatidylglycoside and PS. Third, recent studies have shown that the fatty acid composition of mice with kidney disease undergoes significant changes. The data show that the linoleic acid content in the mouse kidney is significantly increased, while the content of polyunsaturated fatty acids, in particular DHA and EPA is reduced. Therefore, DHA or EPA dietary supplementation can improve the deficiency of polyunsaturated fatty acids in the body of kidney disease mice, thereby promoting kidney recovery. Earlier laboratory studies show that the DHA in phospholipid form can significantly improve the levels of DHA and EPA in tissues compared with ordinary DHA. Although studies have shown that DHA in phospholipid form can improve drug-induced acute kidney injury, there are differences in the pathological mechanisms of acute kidney injury and lupus nephritis. Acute kidney injury is a severe disease mainly caused by renal ischemia or nephrotoxic drugs, the pathogenesis of the acute kidney injury mainly comprises mitochondrial dysfunction, oxidative stress reaction, renal tubular epithelial cell necrosis and apoptosis and the like, and lupus nephritis is mainly closely related to kidney immune complex formation and deposition, inflammation activation and autophagy. Although lysophosphatidylcholine, an active ingredient having good anti-inflammatory activity, has been found to improve various inflammatory diseases such as hepatitis, is a major component of oxidized low density lipoprotein, and in vivo, it activates protein kinase C, causing contraction of vascular smooth muscle, resulting in endothelium-dependent contraction; in addition, it can also destroy the balance of fibrinolysis and blood coagulation system, regulate and control the immune function of mononuclear macrophage and lymphocyte, and may promote atherosclerosis after long-term administration. The phospholipid has various physiological activities, and the dietary supplement of the phospholipid rich in DHA can inhibit in-vivo inflammation, improve the immunity of the organism, improve atherosclerosis and prevent various neurodegenerative diseases. We subsequently analyzed the efficacy difference of the combination of phospholipid and derivatives thereof, common DHA and soybean-derived phospholipid on systemic lupus erythematosus by measuring serum inflammation, immune-related factors and kidney inflammation-related genes.

Further, the product comprises special medical food, health care products, medicines or biological agents, and related products such as emulsion and the like.

Further, said preparation comprises a pharmacologically effective concentration (1% to 100%) of said phospholipid and derivatives thereof as defined in claim 1.

Further, the preparation method of the phospholipid and the derivatives thereof comprises the following steps:

(1) freeze-drying squid eggs or soybeans, then crushing, extracting for 24 hours by using a chloroform/methanol (2: 1, V/V) mixed solution with the volume 15 times, carrying out suction filtration, and extracting for 3 times; adding sodium chloride solution, shaking, standing overnight, collecting lower chloroform layer, and concentrating under reduced pressure to obtain crude extract of squid egg or soybean lipid;

(2) separating the crude lipid extract by normal phase silica gel column chromatography, gradient eluting with chloroform and methanol (90: 10 → 60: 40 → 0: 100, V/V), collecting eluate step by step, concentrating under reduced pressure, detecting the collected components by TLC, mixing the components with the same Rf value, and concentrating under reduced pressure to dry to obtain phosphatidylcholine and phosphatidylethanolamine (series I or series IV, series VI);

(3) preparing a sodium acetate buffer solution with the pH value of 5.6, adding 6% of fructose and 1.5% of Lipozyme435, dissolving in a buffer solution to obtain an aqueous phase, dissolving 20% of the soybean-derived phosphatidylcholine obtained in the step (2) in methanol to obtain an organic phase, and fully mixing the aqueous phase and the organic phase, wherein the ratio of the aqueous phase to the organic phase is 1: 4; stirring the mixture at 37 deg.C for 10 hr, collecting organic phase layer, and removing organic solvent to obtain phosphatidyl glycoside (series II);

(4) and (3) preheating the acetic acid/sodium acetate solution buffer solution in a heat collection type constant temperature heating magnetic stirrer, dissolving L-serine in the buffer solution, adding the phosphatidylcholine from different sources in the step (2), finally adding phospholipase D, stirring at 40 ℃ for reaction for 48 hours, adding hydrochloric acid, inactivating enzyme, terminating the reaction, and extracting reaction products by using n-hexane-isopropanol to obtain soybean phosphatidylserine (series III) and DHA phosphatidylserine (series V).

The invention has the following beneficial effects:

(1) animal experiments show that the phospholipid and the derivatives thereof have obvious effects on improving the systemic lupus erythematosus, and provide a new theoretical way for preventing and treating the systemic lupus erythematosus.

(2) Provides reasonable guidance for the application of the phospholipid and the derivatives thereof in improving the systemic lupus erythematosus products, and has wide market prospect.

Drawings

FIG. 1 is a graph of the results of example 2 of systemic lupus erythematosus in mice affected by skin lesions with phospholipids and derivatives thereof;

FIG. 2 is a graph showing the results of the effect of phospholipids and derivatives thereof on biochemical indicators of serum after intervention of phospholipids and derivatives thereof in mice with systemic lupus erythematosus in example 2;

FIG. 3 is a graph showing spleen weight results of phospholipids and derivatives thereof interfering with SLE mice in example 2;

FIG. 4 is a graph showing the results of the serum inflammation and immune factors after the phospholipid and its derivatives intervene in the phospholipid and its derivatives in the systemic lupus erythematosus in the mice of example 2;

FIG. 5 is a graph showing the results of multiple RNA expression in kidney of example 2 after phospholipid and derivatives thereof intervene in phospholipid and derivatives thereof in SLE mice;

FIG. 6 is a graph showing the expression results of NF- κ B proteins in kidney after phospholipid and its derivatives intervene in phospholipids and their derivatives in SLE mice in example 2.

The specific implementation mode is as follows:

in order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1: preparation of phospholipids and derivatives thereof

(1) Freeze-drying squid eggs or soybeans, then crushing, extracting for 24 hours by using a chloroform/methanol (2: 1, V/V) mixed solution with the volume 15 times, carrying out suction filtration, and extracting for 3 times; adding sodium chloride solution, shaking, standing overnight, collecting lower chloroform layer, and concentrating under reduced pressure to obtain crude extract of squid egg or soybean lipid;

(2) separating the crude lipid extract by normal phase silica gel column chromatography, gradient eluting with chloroform and methanol (90: 10 → 60: 40 → 0: 100, V/V), collecting eluate step by step, concentrating under reduced pressure, detecting the collected components by TLC, mixing the components with the same Rf value, and concentrating under reduced pressure to dry to obtain phosphatidylcholine and phosphatidylethanolamine;

(3) preparing a sodium acetate buffer solution with the pH value of 5.6, adding 6% of fructose and 1.5% of Lipozyme435, dissolving the mixture in a buffer solution to obtain an aqueous phase, dissolving 20% of soybean phosphatidylcholine in methanol to obtain an organic phase, and fully mixing the aqueous phase and the organic phase, wherein the ratio of the aqueous phase to the organic phase is 1: 4; stirring the mixture at 37 ℃ for reaction for 10h, collecting an organic phase layer, and removing the organic solvent to obtain the phosphatidyl glycoside;

(4) and (3) putting the acetic acid/sodium acetate solution buffer solution into a heat collection type constant temperature heating magnetic stirrer for preheating, dissolving L-serine in the buffer solution, adding Soy-PC or DHA-PC in the step (2), finally adding phospholipase D, stirring and reacting for 48 hours at 40 ℃, adding hydrochloric acid, inactivating enzyme, stopping the reaction, and extracting reaction products by using n-hexane-isopropanol to obtain soybean phosphatidylserine (Soy-PS) and DHA phosphatidylserine (DHA-PS).

Example 2: animal experiments

(1) Design of experiments

Six week old MRL/lpr female mice were randomized into 9 groups: the kit comprises a model control group (M), a soybean-derived phosphatidylcholine group (Soy-PC) of a series I, a soybean-derived phosphatidylglycoside group (Soy-PG) of a series II, a soybean-derived phosphatidylserine group (Soy-PS) of a series III, a DHA and soybean-derived phosphatidylcholine complex group (DHA + PC), a DHA and soybean-derived phosphatidylserine complex group (DHA + PS), a DHA-enriched phosphatidylcholine group (DHA-PC) of a series IV, a DHA-enriched phosphatidylserine group (DHA-PS) of a series V, a DHA-enriched phosphatidylethanolamine group (DHA-PE) of a series VI and a C57BL6 female mouse of the same week age as a normal control group (N). Mice were fed modified AIN-93G rodent chow. MRL/lpr mice were fed daily with 1% phospholipid supplemented feed. During which time mouse growth and survival status were recorded. After ten weeks of continuous intervention, mice were fasted overnight and samples such as blood were collected for subsequent biochemical marker detection.

(2) Statistical treatment

The experimental data are expressed in x + -SEM, and Student's t test and Tukey's test analyses were performed using SPSS 18.0 software, with significant differences of P < 0.05.

(3) Results of the experiment

The effect of phospholipids and their derivatives in ameliorating systemic lupus erythematosus is shown in figures 1-6. During feeding, MRL/lpr mice developed typical erythema on the skin surface at sixteen weeks of age, as shown in FIG. 1, indicating that the mice had systemic lupus erythematosus. As the week age of the mice increased, the number of mice with erythema increased significantly, but there was a significant difference between the groups. The number of DHA-enriched phosphatidylcholine-group erythematous mice is obviously lower than that of the model group, and the skin damage degree is lower than that of the model group; DHA-rich phosphatidylserine and ethanolamine are similar, and the number of the two groups of erythema mice is reduced, but the effect is inferior to that of DHA-rich phosphatidylcholine group. The number of the compound erythema mice is less than that of the phospholipid group rich in DHA; the pre-intervention of DHA and soybean phosphatidylcholine can also inhibit erythema generation of model mice, and the effect is better than that of soybean phosphatidylserine and soybean phosphatidylglucoside. Serum biochemical index results are shown in fig. 2, and the anti-dsDNA and anti-ANA levels in the serum of the model group mice were increased about 4-fold compared to the normal group, further indicating that the mice had typical systemic lupus erythematosus. Intervention with different phospholipids or formulations reduced abnormally increased anti-dsDNA and anti-ANA levels in serum of mice with systemic lupus erythematosus. The DHA-rich PC, PS and PE can obviously reduce the abnormally increased dsDNA and ANA antibody content in the serum of the mice, the DHA-PC effect is the most prominent, and the biochemical parameters of the group of mice are approximately restored to the normal level; the compounding of DHA and soybean phospholipids can obviously inhibit the increase of dsDNA and ANA antibodies in mouse serum, but the effect is not as good as that of phospholipid groups rich in DHA; soybean-derived three phospholipid group mice can obviously reduce the content of ANA antibodies in serum, but cannot obviously reduce the content of anti-dsDNA. Spleen is an important immune organ of the body, and the results of organ indexes are shown in figure 3: the spleen index of a model mouse is obviously increased, and the intervention of phosphatidylcholine rich in DHA can inhibit spleen edema of the mouse, and the effect is superior to that of other compounds. In addition, the levels of a plurality of inflammatory factors IL-6, IL-1 beta, MCP-1 and TNF-alpha in the serum of the mouse are obviously higher than those of other groups (figure 4), the intervention of different phospholipids and DHA can inhibit the levels of the inflammatory factors, the DHA-PC effect is most obvious, the DHA-PS and DHA-PE can also reduce the levels of the inflammatory factors in the serum, and the inhibition effect is better than that of the soybean-derived phospholipids and the compound groups. In addition, the serum immune factor results show that the combination of DHA and soybean phospholipids and the phospholipids rich in DHA can improve the content of immune factors IgG and IgM in mice, improve the immune disorder in the mice with systemic lupus erythematosus, the effect of the phospholipids rich in DHA is better than that of the combination, and the phospholipids derived from soybean have the tendency of improving the immunity of organisms (figure 4). The expression of a plurality of inflammation-related genes of the NF-kB pathway of the kidney is further analyzed, and the result is shown in figure 5, and the expression of a plurality of proinflammatory factor genes of the NF-kB pathway in a model mouse is up-regulated, such as MCP-1, IL-1 beta, IL-6, TNF-alpha and p 65; the phospholipid rich in DHA, especially DHA-PC, can obviously inhibit in-vivo inflammatory reaction after being taken for a long time; DHA-PE and DHA-PS have secondary inflammation inhibition activity, and PC, PS and PG derived from soybean can also inhibit the expression of inflammatory factors, but the effect is inferior to that of compounding. Finally, the kidney NF-kB protein expression result shows that the phospholipid rich in DHA can obviously inhibit the activation of NF-kB (figure 6), so that the reaction is inhibited, and the DHA-PC and DHA-PS effects are most obvious and are better than the DHA-PE; in addition, the soybean-derived phosphatidylcholine and DHA can be compounded to inhibit the expression of NF-kB, so that the NF-kB signal channel is inhibited. The experimental results show that: the improvement effect of the phospholipid rich in DHA on systemic lupus erythematosus is superior to that of the compound of soybean phospholipid and DHA and soybean phospholipid, the improvement effect of the phosphatidylcholine rich in DHA is superior to that of the phosphatidylserine and phosphatidylethanolamine rich in DHA, and the improvement effect of the phosphatidylcholine derived from soybean is similar to that of phosphatidylserine and phosphatidylglycoside. The phospholipid and the derivatives thereof are probably related to improvement of the skin and kidney injuries of the mice with the systemic lupus erythematosus, and further mechanism research shows that the phospholipid and the derivatives thereof can inhibit the activation of NF-kB in vivo and further inhibit the activation of proinflammatory factors, so that the inflammatory reaction in the mice with the systemic lupus erythematosus is inhibited, the immune balance of the body is restored, and the systemic lupus erythematosus is improved.

The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. However, any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention are within the protection scope of the technical solution of the present invention.